Tumor suppressor protein p53 negatively regulates human pregnane x receptor activitys

Molecular Pharmacology

Volumn 83, Issue 6, 2013, Pages 1229-1236

  Elias, Ayesha ^a   Wu, Jing ^a   Chen, Taosheng ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREGNANE X RECEPTOR; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE DELETION; GENE REPRESSION; HUMAN; HUMAN CELL; LIGAND BINDING; LOSS OF FUNCTION MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING; WILD TYPE;

CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN INTERACTION MAPS; RECEPTORS, STEROID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877803927     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.085092     Document Type: Article

References (44)

1. Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, and Choubey D (2007) Expression of androgen receptor is negatively regulated by p53. Neoplasia 9: 1152-1159. (Pubitemid 350255362)
2. Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, and Saceda M (2004) Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 180:497-504. (Pubitemid 38443401)
3. Blandino G, Levine AJ, and Oren M (1999) Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477-485. (Pubitemid 29060623)
4. Blumberg B, Kang H, Bolado J, Jr, Chen H, Craig AG, Moreno TA, Umesono K, Perlmann T, De Robertis EM, and Evans RM (1998a) BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites. Genes Dev 12:1269-1277. (Pubitemid 28213403)
5. Blumberg B, Sabbagh W, Jr, Juguilon H, Bolado J, Jr, van Meter CM, Ong ES, and Evans RM (1998b) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205. (Pubitemid 28496264)
6. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, and Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501. (Pubitemid 28538613)
7. Chen Y, Tang Y, Wang MT, Zeng S, and Nie D (2007) Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res 67:10361-10367. (Pubitemid 350070811)
8. Ding X and Staudinger JL (2005) Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C. Biochem Pharmacol 69:867-873. (Pubitemid 40248628)
9. Dotzlaw H, Leygue E, Watson P, and Murphy LC (1999) The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin Cancer Res 5:2103-2107. (Pubitemid 29399265)
10. El-Deiry WS (2003) The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495. (Pubitemid 37487171)
11. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Jr, Magrath I, Kohn KW, and O'Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824-5830.
12. Fan S, Smith ML, Rivet DJ, 2nd, Duba D, Zhan Q, Kohn KW, Fornace AJ, Jr, and O'Connor PM (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654.
13. Fojo T (2002) p53 as a therapeutic target: Unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist Updat 5:209-216. (Pubitemid 35429451)
14. Goodwin B, Redinbo MR, and Kliewer SA (2002) Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol 42:1-23. (Pubitemid 34160517)
15. Hainaut P and Hollstein M (2000) p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 77:81-137. (Pubitemid 29439303)
16. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991) p53 mutations in human cancers. Science 253:49-53. (Pubitemid 21917115)
17. Iwano S, Shibahara N, Saito T, and Kamataki T (2006) Activation of p53 as a causal step for atherosclerosis induced by polycyclic aromatic hydrocarbons. FEBS Lett 580:890-893. (Pubitemid 43152310)
18. Johnson DR, Li CW, Chen LY, Ghosh JC, and Chen JD (2006) Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT). Mol Pharmacol 69:99-108. (Pubitemid 43048897)
19. Kern SE, Pietenpol JA, ThiagalingamS, Seymour A, Kinzler KW, and Vogelstein B (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
20. Kliewer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr Rev 23:687-702. (Pubitemid 35191629)
21. Kodama S, Koike C, Negishi M, and Yamamoto Y (2004) Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol 24:7931-7940. (Pubitemid 39167443)
22. Lamba V, Yasuda K, Lamba JK, Assem M, Davila J, Strom S, and Schuetz EG (2004) PXR (NR1I2): Splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol Appl Pharmacol 199:251-265. (Pubitemid 39208725)
23. Levine AJ, Hu W, and Feng Z (2006) The P53 pathway: What questions remain to be explored? Cell Death Differ 13:1027-1036.
24. Lin J, Chen J, Elenbaas B, and Levine AJ (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8:1235-1246. (Pubitemid 24163450)
25. Lin W, Wu J, Dong H, Bouck D, Zeng FY, and Chen T (2008) Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem 283:30650-30657.
26. Lin YS, Yasuda K, Assem M, Cline C, Barber J, Li CW, Kholodovych V, Ai N, Chen JD, and Welsh WJ et al. (2009) The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos 37:1295-1304.
27. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, and Gilbert D, et al. (2002) CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804. (Pubitemid 34671092)
28. Maeda Y, Seidel SD, Wei G, Liu X, and Sladek FM (2002) Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: Involvement of the ligand-binding domain and histone deacetylase activity. Mol Endocrinol 16:402-410. (Pubitemid 34131234)
29. Mani S, Dou W, and Redinbo MR (2013) PXR antagonists and implication in drug metabolism. Drug Metab Rev 45:60-72.
30. Menendez D, Inga A, and Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9:724-737.
31. Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK, and Rosenfeld MG (1999) Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 13:3198-3208. (Pubitemid 30030442)
32. Picksley SM, Vojtesek B, Sparks A, and Lane DP (1994) Immunochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9:2523-2529. (Pubitemid 24254027)
33. Plevin MJ, Mills MM, and Ikura M (2005) The LxxLL motif: A multifunctional binding sequence in transcriptional regulation. Trends Biochem Sci 30:66-69. (Pubitemid 40187297)
34. Pondugula SR and Mani S (2013) Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett 328:1-9.
35. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji J, and Ozturk M (1993) Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 7:1407-1413. (Pubitemid 23336171)
36. Raynal C, Pascussi JM, Leguelinel G, Breuker C, Kantar J, Lallemant B, Poujol S, Bonnans C, Joubert D, and Hollande F et al. (2010) Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer 9:46.
37. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, and Costa J (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4499.
38. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, and Shemshedini L (2001) p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino-to carboxyl-terminal interaction. J Biol Chem 276: 38472-38479.
39. Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ, and Fuchs-Young R (2009) Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res 69:3405-3414.
40. Soussi T and Wiman KG (2007) Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 12:303-312. (Pubitemid 47539312)
41. Wang H, Venkatesh M, Li H, Goetz R, Mukherjee S, Biswas A, Zhu L, Kaubisch A, Wang L, and Pullman J et al. (2011) Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest 121: 3220-3232.
42. Wang YM, Ong SS, Chai SC, and Chen T (2012) Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol 8:803-817.
43. Watkins RE, Davis-Searles PR, Lambert MH, and Redinbo MR (2003) Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331:815-828. (Pubitemid 36945439)
44. Yu C, Yap N, Chen D, and Cheng S (1997) Modulation of hormone-dependent transcriptional activity of the glucocorticoid receptor by the tumor suppressor p53. Cancer Lett 116:191-196. (Pubitemid 27283007)